Ascentage Pharma presents Phase II China study on Lisaftoclax at ASH Annual Meeting, supporting NDA approval by NMPA in July 2025.
On December 6, 2025, Ascentage Pharma Group International Inc. disclosed at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, FL, that their Phase II study in China involving Lisaftoclax (APG-2575) for relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma patients who failed Bruton’s tyrosine kinase inhibitors (BTKis) was successful. The National Medical Products Administration (NMPA) of China approved Lisaftoclax in July 2025 following data from this critical trial. Ascentage Pharma Group, a biopharmaceutical company traded on NASDAQ (AAPG) and HKEX (6855), specializes in developing innovative therapies for cancer treatment.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments